biostudies-literatureUnknown13(10)Aragona PSIFI<h4>Introduction</h4>Patients with dry eye disease (DED) complain of a multitude of symptoms that affect their visual function and quality of life (QoL). This clinical investigation assessed the performance, tolerance, and safety of a novel preservative-free ophthalmic solution containing xanthan gum 0.2% and desonide sodium phosphate 0.025%.<h4>Methods</h4>This was an observational, prospective, multicentric, and post-market clinical investigation to assess the effect of three times a day instillation of the study formulation in patients suffering from DED. The primary objective was to achieve a 50% reduction in conjunctival hyperemia index as assessed with the OCULUS Keratograph after 1 month of treatment compared to baseline values. The secondary objectives included patient-reported outOphthalmology and therapy2559-2573https://www.ebi.ac.uk/biostudies/studies/S-EPMC11408441biostudies-literatureObservational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment.PMC11408441Dammino EGiannaccare GD'Esposito FGenovese PGagliano CPostorino EIMazzone MGAragona PCiviale CfalseObservational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment.<h4>Introduction</h4>Patients with dry eye disease (DED) complain of a multitude of symptoms that affect their visual function and quality of life (QoL). This clinical investigation assessed the performance, tolerance, and safety of a novel preservative-free ophthalmic solution containing xanthan gum 0.2% and desonide sodium phosphate 0.025%.<h4>Methods</h4>This was an observational, prospective, multicentric, and post-market clinical investigation to assess the effect of three times a day instillation of the study formulation in patients suffering from DED. The primary objective was to achieve a 50% reduction in conjunctival hyperemia index as assessed with the OCULUS Keratograph after 1 month of treatment compared to baseline values. The secondary objectives included patient-reported out2024-01-01T00:00:00Z2024 Oct2026-06-03T22:03:06.764Z2025-04-04T02:54:16.401ZS-EPMC114084413906070010.1007/s40123-024-01003-z